Jason Bednar
Stock Analyst at Piper Sandler
(2.24)
# 2,680
Out of 4,761 analysts
158
Total ratings
46.46%
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Jason Bednar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KRMD KORU Medical Systems | Downgrades: Neutral | $4.5 | $3.71 | +21.29% | 6 | Feb 14, 2025 | |
| ALGN Align Technology | Maintains: Overweight | $275 → $270 | $190.43 | +41.78% | 28 | Feb 6, 2025 | |
| STE STERIS | Maintains: Overweight | $260 → $265 | $220.56 | +20.15% | 9 | Feb 3, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $17 → $18 | $20.87 | -13.75% | 11 | Feb 3, 2025 | |
| MMSI Merit Medical Systems | Reiterates: Overweight | $114 → $116 | $103.16 | +12.45% | 9 | Jan 29, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $275 → $280 | $227.43 | +23.11% | 7 | Jan 28, 2025 | |
| MASI Masimo | Maintains: Overweight | $180 → $210 | $169.96 | +23.56% | 13 | Dec 18, 2024 | |
| NVCR NovoCure | Maintains: Overweight | $28 → $42 | $22.09 | +90.13% | 9 | Dec 13, 2024 | |
| PDCO Patterson Companies | Maintains: Neutral | $26 → $24 | $31.07 | -22.76% | 9 | Dec 6, 2024 | |
| SOLV Solventum | Maintains: Neutral | $71 → $75 | $73.02 | +2.71% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $6 | $1.86 | +222.58% | 5 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $115 → $120 | $88.48 | +35.62% | 11 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $2.68 | +161.19% | 5 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3.5 → $1 | $0.35 | +185.47% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $8.96 | +33.93% | 10 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 | $77.24 | +11.34% | 6 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $13 | $13.52 | -3.85% | 1 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $35 → $32 | $18.75 | +70.67% | 7 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $372 | $591.79 | -37.14% | 4 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $9 | $2.58 | +248.84% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $95 | $91.09 | +4.29% | 1 | Apr 19, 2023 |
KORU Medical Systems
Feb 14, 2025
Downgrades: Neutral
Price Target: $4.5
Current: $3.71
Upside: +21.29%
Align Technology
Feb 6, 2025
Maintains: Overweight
Price Target: $275 → $270
Current: $190.43
Upside: +41.78%
STERIS
Feb 3, 2025
Maintains: Overweight
Price Target: $260 → $265
Current: $220.56
Upside: +20.15%
Envista Holdings
Feb 3, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $20.87
Upside: -13.75%
Merit Medical Systems
Jan 29, 2025
Reiterates: Overweight
Price Target: $114 → $116
Current: $103.16
Upside: +12.45%
Becton, Dickinson and Company
Jan 28, 2025
Maintains: Overweight
Price Target: $275 → $280
Current: $227.43
Upside: +23.11%
Masimo
Dec 18, 2024
Maintains: Overweight
Price Target: $180 → $210
Current: $169.96
Upside: +23.56%
NovoCure
Dec 13, 2024
Maintains: Overweight
Price Target: $28 → $42
Current: $22.09
Upside: +90.13%
Patterson Companies
Dec 6, 2024
Maintains: Neutral
Price Target: $26 → $24
Current: $31.07
Upside: -22.76%
Solventum
Nov 8, 2024
Maintains: Neutral
Price Target: $71 → $75
Current: $73.02
Upside: +2.71%
Nov 7, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $1.86
Upside: +222.58%
Aug 29, 2024
Reiterates: Overweight
Price Target: $115 → $120
Current: $88.48
Upside: +35.62%
Aug 15, 2024
Reiterates: Overweight
Price Target: $7
Current: $2.68
Upside: +161.19%
Aug 7, 2024
Maintains: Overweight
Price Target: $3.5 → $1
Current: $0.35
Upside: +185.47%
Aug 1, 2024
Maintains: Overweight
Price Target: $14 → $12
Current: $8.96
Upside: +33.93%
Jun 21, 2024
Reiterates: Overweight
Price Target: $86
Current: $77.24
Upside: +11.34%
May 21, 2024
Initiates: Neutral
Price Target: $13
Current: $13.52
Upside: -3.85%
May 3, 2024
Reiterates: Neutral
Price Target: $35 → $32
Current: $18.75
Upside: +70.67%
Jan 3, 2024
Maintains: Outperform
Price Target: $310 → $372
Current: $591.79
Upside: -37.14%
Nov 10, 2023
Maintains: Overweight
Price Target: $14 → $9
Current: $2.58
Upside: +248.84%
Apr 19, 2023
Initiates: Overweight
Price Target: $95
Current: $91.09
Upside: +4.29%